151 related articles for article (PubMed ID: 34336233)
1. Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries.
Mitropoulos D; Chlosta P; Häggman M; Ström T; Markussis V
Cent European J Urol; 2021; 74(2):161-168. PubMed ID: 34336233
[TBL] [Abstract][Full Text] [Related]
2. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
3. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
Cornford P; van den Bergh RCN; Briers E; Van den Broeck T; Cumberbatch MG; De Santis M; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Grummet J; Henry AM; der Kwast THV; Lam TB; Lardas M; Liew M; Mason MD; Moris L; Oprea-Lager DE; der Poel HGV; Rouvière O; Schoots IG; Tilki D; Wiegel T; Willemse PM; Mottet N
Eur Urol; 2021 Feb; 79(2):263-282. PubMed ID: 33039206
[TBL] [Abstract][Full Text] [Related]
4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
5. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
MacLennan S; Azevedo N; Duncan E; Dunsmore J; Fullwood L; Lumen N; Plass K; Ribal MJ; Roobol MJ; Nieboer D; Schouten N; Skolarus TA; Smith EJ; N'Dow J; Mottet N; Briganti A;
Eur Urol; 2023 May; 83(5):393-401. PubMed ID: 36639296
[TBL] [Abstract][Full Text] [Related]
6. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; van den Bergh RCN; Briers E; Van den Broeck T; Cumberbatch MG; De Santis M; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Grummet J; Henry AM; van der Kwast TH; Lam TB; Lardas M; Liew M; Mason MD; Moris L; Oprea-Lager DE; van der Poel HG; Rouvière O; Schoots IG; Tilki D; Wiegel T; Willemse PM; Cornford P
Eur Urol; 2021 Feb; 79(2):243-262. PubMed ID: 33172724
[TBL] [Abstract][Full Text] [Related]
7. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
Cornford P; van den Bergh RCN; Briers E; Van den Broeck T; Brunckhorst O; Darraugh J; Eberli D; De Meerleer G; De Santis M; Farolfi A; Gandaglia G; Gillessen S; Grivas N; Henry AM; Lardas M; van Leenders GJLH; Liew M; Linares Espinos E; Oldenburg J; van Oort IM; Oprea-Lager DE; Ploussard G; Roberts MJ; Rouvière O; Schoots IG; Schouten N; Smith EJ; Stranne J; Wiegel T; Willemse PM; Tilki D
Eur Urol; 2024 Apr; ():. PubMed ID: 38614820
[TBL] [Abstract][Full Text] [Related]
8. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
[TBL] [Abstract][Full Text] [Related]
9. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
Tilki D; van den Bergh RCN; Briers E; Van den Broeck T; Brunckhorst O; Darraugh J; Eberli D; De Meerleer G; De Santis M; Farolfi A; Gandaglia G; Gillessen S; Grivas N; Henry AM; Lardas M; J L H van Leenders G; Liew M; Linares Espinos E; Oldenburg J; van Oort IM; Oprea-Lager DE; Ploussard G; Roberts MJ; Rouvière O; Schoots IG; Schouten N; Smith EJ; Stranne J; Wiegel T; Willemse PM; Cornford P
Eur Urol; 2024 Apr; ():. PubMed ID: 38688773
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
Shore ND; Antonarakis ES; Cookson MS; Crawford ED; Morgans AK; Albala DM; Hafron J; Harris RG; Saltzstein D; Brown GA; Henderson J; Lowentritt B; Spier JM; Concepcion R
Prostate; 2020 May; 80(6):527-544. PubMed ID: 32130741
[TBL] [Abstract][Full Text] [Related]
11. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
12. Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study.
Morgia G; Russo GI; Tubaro A; Bortolus R; Randone D; Gabriele P; Trippa F; Zattoni F; Porena M; Mirone V; Serni S; Del Nero A; Lay G; Ricardi U; Rocco F; Terrone C; Pagliarulo A; Ludovico G; Vespasiani G; Brausi M; Simeone C; Novella G; Carmignani G; Leonardi R; Pinnarò P; De Paula U; Corvò R; Tenaglia R; Siracusano S; Mantini G; Gontero P; Savoca G; Ficarra V;
BJU Int; 2016 Jun; 117(6):867-73. PubMed ID: 26332130
[TBL] [Abstract][Full Text] [Related]
13. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
14. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
[TBL] [Abstract][Full Text] [Related]
15. International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.
Liede A; Hallett DC; Hope K; Graham A; Arellano J; Shahinian VB
ESMO Open; 2016; 1(2):e000040. PubMed ID: 27843596
[TBL] [Abstract][Full Text] [Related]
16. Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice.
Payne H; McMenemin R; Bahl A; Greene D; Staffurth J
Int J Clin Pract; 2019 Sep; 73(9):1-6. PubMed ID: 30414348
[TBL] [Abstract][Full Text] [Related]
17. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study).
Lam TBL; MacLennan S; Willemse PM; Mason MD; Plass K; Shepherd R; Baanders R; Bangma CH; Bjartell A; Bossi A; Briers E; Briganti A; Buddingh KT; Catto JWF; Colecchia M; Cox BW; Cumberbatch MG; Davies J; Davis NF; De Santis M; Dell'Oglio P; Deschamps A; Donaldson JF; Egawa S; Fankhauser CD; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Gross T; Grummet JP; Henry AM; Ingels A; Irani J; Lardas M; Liew M; Lin DW; Moris L; Omar MI; Pang KH; Paterson CC; Renard-Penna R; Ribal MJ; Roobol MJ; Rouprêt M; Rouvière O; Sancho Pardo G; Richenberg J; Schoots IG; Sedelaar JPM; Stricker P; Tilki D; Vahr Lauridsen S; van den Bergh RCN; Van den Broeck T; van der Kwast TH; van der Poel HG; van Leenders GJLH; Varma M; Violette PD; Wallis CJD; Wiegel T; Wilkinson K; Zattoni F; N'Dow JMO; Van Poppel H; Cornford P; Mottet N
Eur Urol; 2019 Dec; 76(6):790-813. PubMed ID: 31587989
[TBL] [Abstract][Full Text] [Related]
18. Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study.
Rijksen BLT; Pos FJ; Hulshof MCCM; Vernooij RWM; Jansen H; van Andel G; Wijsman BP; Somford DM; Busstra MB; van Moorselaar RJA; Kaa CAH; van Leenders GJLH; Hamberg P; van den Berkmortel F; Fütterer JJ; Kiemeney LA; van Oort IM; Aben KKH
Eur Urol Focus; 2021 Mar; 7(2):332-339. PubMed ID: 31748122
[TBL] [Abstract][Full Text] [Related]
19. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer.
Ozyigit G; Hurmuz P; Yuce D; Akyol F
World J Clin Oncol; 2019 Aug; 10(8):283-292. PubMed ID: 31528544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
